Cylene Pharmaceuticals

closed

A clinical stage private company designing and developing small molecule drugs against newly validated cancer targets.

Launch date

2001

Employees

Market cap

Enterprise valuation

San Diego California (HQ)

Date	Investors	Amount	Round
Oct 2001	Sanderling Ventures Novartis Venture Fund Research Corporation Technologies	$3.5m	Series A
May 2005	Mitsui Global Investment Bioventures Investors William Harris Investors	$26.3m	Series B
Jan 2007	Mitsui Global Investment Lilly Ventures Bioventures Investors Celgene Sanderling Ventures HBM Healthcare Investments	$44.0m	Series C
Sep 2010	Morningside Group Mitsui Global Investment Lilly Ventures Bioventures Investors Novartis Venture Fund	$12.0m	Series D
Aug 2011	N/A	$15.6m	Debt
Jan 2013	Lilly Ventures	$867k	Debt
Total Funding		€78.0m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Cylene Pharmaceuticals